Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Sam Citron who wrote (9730)	12/11/2003 4:18:45 PM
From: Biomaven	Read Replies (2) \| Respond to of 52153

Sam, CROs already have a big chunk of the market. For example, SEPR's biggest expense by far is payments to CROs. It always seemed to me like the industry should do well, but they never seem to. Don't know if it's bad management or too much competition or what. Maybe when pharma starts belt-tightening it will end up helping the CROs. QTRN (Quintiles) had an interesting hybrid idea - they also funded marketing in exchange for a piece of the action - a good example was for SCIO's Natrecor. Didn't seem to help QTRN any in the long run though. A good growth area must likely come from running foreign trials in places it's easier to recruit victims (patients). Has to be someplace that doesn't raise too many eyebrows in the US. Peter